下一代测序诊断在脓毒性休克患者中的性能优于标准微生物学诊断
本研究为前瞻性观察性单中心研究的二次分析,纳入48例脓毒性休克患者(共256份血浆样本,28天内最多7个连续时间点)及20例无感染的择期手术对照。对血浆游离DNA行下一代测序及相关性评分,并与配对的培养法诊断(如血培养)比较,由独立专家小组评估结果可信性及抗生素治疗恰当性。脓毒症起病时血培养阳性率为33%,下一代测序病原体鉴定阳性率为72%;整个研究期间血培养阳性率11%,下一代测序阳性率71%。96%的急性脓毒症时间点阳性下一代测序结果被认为可信,其中53%的病例据此可调整为更恰当的治疗。
要点
- 脓毒症起病时,下一代测序病原体鉴定阳性率为72%,血培养阳性率为33%。
- 整个研究期间,下一代测序阳性率为71%,血培养阳性率为11%。
- 急性脓毒症时间点阳性下一代测序结果中96%被专家小组认为可信。
- 专家评估认为,53%的阳性下一代测序结果可促成调整为更恰当的抗感染治疗。
- 该诊断平台在脓毒性休克患者中显示出比血培养更高的敏感性和特异性。
适用人群与场景
- 48例脓毒性休克患者(来自50例脓毒性休克患者,共256份血浆样本,28天观察期内最多7个连续时间点)。
- 20例无感染的择期手术患者作为对照队列。
- 场景:大学医院外科ICU及研究实验室。
研究设计与关键结果
- 研究设计:前瞻性观察性单中心研究的二次分析;无干预。
- 样本:48例脓毒性休克患者提供256份血浆样本;对照为20例无感染择期手术患者。
- 干预与对照:血浆游离DNA行下一代测序及相关性评分,与配对的培养法诊断(如血培养)比较;由独立专家小组评估结果可信性及抗生素治疗恰当性。
- 主要结果:脓毒症起病时,下一代测序病原体鉴定阳性率72%,血培养阳性率33%。
- 整个研究期间:血培养阳性率11%,下一代测序阳性率71%。
- 急性脓毒症时间点阳性下一代测序结果中96%被认为可信;专家评估认为53%的病例可据此调整为更恰当的治疗。
证据类型、等级与局限
- 证据类型:前瞻性观察性单中心研究的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于下一代测序的血液感染分析为鉴定临床相关病原体提供了有价值的诊断平台,敏感性和特异性高于血培养,提示患者可能从基于下一代测序诊断的更恰当治疗中获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Culture-based diagnostics represent the standard of care in septic patients, but are highly insensitive and in many cases unspecific. We recently demonstrated the general feasibility of next-generation sequencing-based diagnostics using free circulating nucleic acids (cell-free DNA) in plasma samples of septic patients. Within the presented investigation, higher performance of next-generation sequencing-based diagnostics was validated by comparison to matched blood cultures.
DESIGN: A secondary analysis of a prospective, observational, single-center study.
SETTING: Surgical ICU of a university hospital and research laboratory.
PATIENTS: Fifty patients with septic shock, 20 uninfected patients with elective surgery as control cohort.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: From 256 plasma samples of 48 septic patients at up to seven consecutive time points within the 28-day observation period, cell-free DNA was isolated and analyzed by next-generation sequencing and relevance scoring. In parallel, results from culture-based diagnostics (e.g., blood culture) were obtained. Plausibility of blood culture and next-generation sequencing results as well as adequacy of antibiotic therapy was evaluated by an independent expert panel. In contrast to blood culture with a positivity rate of 33% at sepsis onset, the positivity rate for next-generation sequencing-based pathogen identification was 72%. Over the whole study period, blood culture positivity was 11%, and next-generation sequencing positivity was 71%. Ninety-six percent of positive next-generation sequencing results for acute sepsis time points were plausible and would have led to a change to a more adequate therapy in 53% of cases as assessed by the expert evaluation.
CONCLUSIONS: Our results show that next-generation sequencing-based analyses of bloodstream infections provide a valuable diagnostic platform for the identification of clinically relevant pathogens with higher sensitivity and specificity than blood culture, indicating that patients might benefit from a more appropriate therapy based on next-generation sequencing-based diagnosis.
参考来源
- Grumaz S, Grumaz C, Vainshtein Y, et al. Enhanced Performance of Next-Generation Sequencing Diagnostics Compared With Standard of Care Microbiological Diagnostics in Patients Suffering From Septic Shock. Crit Care Med. 2019. PMID: 30720537. doi:10.1097/CCM.0000000000003658
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。